Pharming Group (PHAR) versus Its Peers Head to Head Review

Pharming Group (NASDAQ:PHAR – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Pharming Group to related businesses based on the strength of its earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Pharming Group and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pharming Group 6.23% 8.70% 4.93%
Pharming Group Competitors -12,224.09% -202.33% -31.23%

Analyst Ratings

This is a summary of current ratings and target prices for Pharming Group and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group 0 2 3 0 2.60
Pharming Group Competitors 9923 15313 45674 1602 2.54

Pharming Group currently has a consensus price target of $39.67, indicating a potential upside of 214.81%. As a group, “Biotechnology” companies have a potential upside of 126.38%. Given Pharming Group’s stronger consensus rating and higher probable upside, research analysts plainly believe Pharming Group is more favorable than its rivals.

Institutional and Insider Ownership

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Pharming Group has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Pharming Group’s rivals have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.

Valuation and Earnings

This table compares Pharming Group and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pharming Group $386.75 million $2.85 million 39.38
Pharming Group Competitors $755.30 million $11.71 million -18.77

Pharming Group’s rivals have higher revenue and earnings than Pharming Group. Pharming Group is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Pharming Group beats its rivals on 7 of the 13 factors compared.

About Pharming Group

(Get Free Report)

Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.